Auris reports additional Phase III data of brimapitide for hearing loss

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256 patients with severe to profound idiopathic sudden sensorineural hearing loss.

Low-dose brimapitide led to an 11.4% incidence of no hearing improvement by day 91 vs. 38.2% for placebo (p=0.012). Low-dose brimapitide also led to an improvement in speech discrimination as measured by correctly recognized words at day 91 by 49.2 percentage points vs. 30.4 percentage points for placebo (p=0.062)...